Fundraising Fox
Mirabiologics
Tokyo, JP · 1 known investors
Find your way into Mirabiologics
Sign up to see every warm intro you have to Mirabiologics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Mirabiologics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
MiraBiologics is a Japanese biopharmaceutical drug discovery company that uses its LassoGraft Technology to graft cyclic peptides onto scaffold proteins for the development of novel biologics. It pursues collaborative R&D partnerships to create innovative biopharmaceuticals.
Founders & leadership
JT
Junichi TakagiCo-founder; Director & Professor, Osaka University
MK
Masuhiro KatoRepresentative Director & PresidentMasuhiro Kato spent over 45 years in pharmaceutical R&D and served as R&D Director and later President and Chairman of AstraZeneca Japan. He subsequently held a position as Translational Research Professor at the University of Tokyo before co-founding MiraBiologics in 2017 with Professors Suga and Takagi to develop biologics using the LassoGraft Technology platform.
I
IgarashiChief Operating Officer
Investors · 1
Frequently asked questions
- What does Mirabiologics do?
- MiraBiologics is a Japanese biopharmaceutical drug discovery company that uses its LassoGraft Technology to graft cyclic peptides onto scaffold proteins for the development of novel biologics. It pursues collaborative R&D partnerships to create innovative biopharmaceuticals.
- Who founded Mirabiologics?
- Mirabiologics was founded by Hiroaki Suga, Junichi Takagi.
- Who are Mirabiologics's investors?
- Mirabiologics's investors include Shinsei Capital Partners.
- Where is Mirabiologics headquartered?
- Mirabiologics is headquartered in Tokyo, JP.